Si-Bone Stock Price, News & Analysis

SI-BONE, Inc. (Nasdaq: SIBN) announced on July 14, 2021, that Centene Corporation has implemented a positive coverage policy for the iFuse Implant System, a treatment for chronic sacroiliac joint pain. This policy recognizes minimally invasive SI joint fusion as a medically necessary procedure when specific criteria are met, enhancing patient access. Centene serves over 25 million members and aims to improve treatment availability for low-income individuals. The policy reflects extensive clinical evidence supporting the safety and effectiveness of the iFuse system.

SI-BONE, Inc. (Nasdaq: SIBN) has released promising 24-month results from the SALLY study, showcasing the efficacy of the iFuse-3D™ Implant System in treating sacroiliac joint pain. The study reported a significant decline in opioid use from 59% to 18% and consistent improvements in patient function and quality of life. This follows earlier studies endorsing the iFuse implant's safety and effectiveness. The iFuse-3D implant, designed for enhanced bone integration, is expected to further bolster the company's market position in the medical device sector.

SI-BONE, Inc. (SIBN) has launched the SI-BONE SImulator™, a revolutionary training simulation system for surgeons. This innovative platform is designed to enhance the learning of SI-BONE sacropelvic procedures, including iFuse procedures, using radiation-free technology. The SImulator can be utilized in various settings without traditional imaging equipment, making it accessible and portable. The collaboration with Medability has resulted in a versatile training tool that supports both group and individual training sessions and focuses on patient-specific anatomies.

SI-BONE, Inc. (Nasdaq: SIBN) announced national reimbursement for the iFuse-3D Implant System™ by the French Health Ministry, effective June 1, 2021, for five years. This follows a positive opinion from the Haute Autorité de Santé recognizing the implant's therapeutic benefits for sacroiliac joint dysfunction. The implant is the first 3D-printed titanium solution for SI joint fusion, designed for effective bony integration. With reimbursement confirmed, patient access in France improves, allowing surgeons to leverage this technology for various pelvic and spinal conditions.

SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2021 JMP Securities Life Sciences Conference. The company is set to present on June 17 at 2:30 p.m. ET. Interested parties can access a live and archived webcast on the company’s website. SI-BONE specializes in minimally invasive surgery of the SI joint with its iFuse Implant System, which has demonstrated effectiveness for treating chronic low back pain associated with sacroiliac joint dysfunction.

SI-BONE, Inc. (SIBN) reported Q1 2021 revenue of $20.4 million, marking a 22% increase from Q1 2020. U.S. revenue reached $18.8 million, up 23% year-over-year. The company launched the iFuse-TORQ implant to address pelvic trauma needs and has transitioned its leadership team, appointing Laura Francis as CEO. Operating loss narrowed to $11.6 million from $11.9 million in 2020. Despite a cautious outlook due to COVID-19, SIBN anticipates 2021 revenue of $92 million to $94 million, projecting a 25% to 28% growth.

SI-BONE, a medical device company focused on sacropelvic disorders, will participate in two key events: the 7th Annual Truist Securities 2021 Life Sciences Summit on May 5, 2021, and the 2021 Bank of America Health Care Conference on May 12, 2021. During the Truist Securities event, management will host a Fireside Chat at 2:40 p.m. ET, and at the Bank of America Conference, they will present at 8:00 a.m. ET. Interested parties can view live and archived webcasts on the company’s website.

SI-BONE, Inc. (SIBN) announced significant leadership changes, appointing Anshul Maheshwari as Chief Financial Officer effective April 20, 2021. The transition also includes Laura Francis taking over as CEO, while Jeff Dunn remains Executive Chairman. Maheshwari brings over 15 years of experience, including his role at Varian Medical Systems. Additionally, Helen Loh and Laura Francis are new Board members, expected to enhance SI-BONE's strategy and marketing efforts. These changes aim to strengthen the company's growth and operational capabilities.

SI-BONE, Inc. (Nasdaq: SIBN) will report Q1 2021 financial results after market close on May 3, 2021. This announcement includes a conference call at 1:30 PM PT / 4:30 PM ET, accessible via phone or webcast on their website. The iFuse Implant System, the company's primary product for treating sacroiliac joint dysfunction, has shown positive clinical outcomes supported by multiple studies. Since 2009, iFuse has been the only SI joint fusion device with established insurance coverage based on its clinical effectiveness and safety.